Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications
Rhea-AI Summary
Reviva (NASDAQ: RVPH) announced that CEO Laxminarayan Bhat, PhD, will participate in an A.G.P. fireside chat on April 27, 2026 at 11:00 AM ET to discuss the clinical-stage drug candidate brilaroxazine and upcoming clinical, regulatory, and IP milestones.
A live webcast link is available for investors and interested parties to watch the discussion.
Positive
- None.
Negative
- None.
News Market Reaction – RVPH
In the Apr 23 session, RVPH declined 4.17%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 15 | Shareholder letter update | Positive | +3.4% | Shareholder letter outlining financing, cash position, and brilaroxazine development plans. |
| Mar 30 | Full-year earnings | Negative | -11.0% | Full-year 2025 net loss and update on need for second Phase 3 trial. |
| Mar 23 | Offering closed | Negative | +11.6% | Closing of $10M public offering with warrants and updated post-close cash balance. |
| Mar 18 | Offering priced | Negative | -55.4% | Pricing of $10M public offering with Series G and H warrants at $1.50. |
| Mar 18 | Offering proposed | Negative | -55.4% | Announcement of intent to conduct public offering to fund RECOVER-2 and working capital. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows large negative reactions to offering announcements, a positive response to the offering close, and generally aligned moves around financing and shareholder updates.
Over the last several months, RVPH news has centered on financing, capital structure, and advancing brilaroxazine. A shareholder letter on Apr 15, 2026 highlighted cash of about $23M and plans for the RECOVER-2 Phase 3 trial, with shares up 3.35%. Multiple March $10M offering announcements led to sharp moves, including a -55.43% reaction to the proposed and priced offerings and a later 11.63% gain on closing. Today’s fireside chat continues the communication around clinical and regulatory milestones for brilaroxazine.
Key Terms
central nervous system (cns) medical
cardiometabolic medical
neuropsychiatric medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CUPERTINO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat hosted by A.G.P. Equity Research Analyst James Molloy on Monday, April 27, 2026 at 11:00 AM ET.
The fireside chat will highlight the recent developments from Reviva’s clinical stage drug candidate brilaroxazine and upcoming clinical, regulatory, and IP milestones.
A.G.P. Fireside Chat
Format: Fireside Chat
Date: Monday, April 27, 2026
Time: 11:00 a.m. ET
Webcast Link: CLICK HERE
About Brilaroxazine
Brilaroxazine is an in-house discovered new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in the pathophysiology of several conditions including schizophrenia, psoriasis and interstitial lung diseases like pulmonary hypertension, pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Positive topline data from the global Phase 3 RECOVER trial in schizophrenia demonstrated the trial successfully met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains including reduction in key proinflammatory cytokines implicated in the pathophysiology of schizophrenia and comorbid inflammatory conditions at week 4 with 50 mg of brilaroxazine vs. placebo, with a generally well-tolerated side effect profile comparable to placebo and discontinuation rates lower than placebo. Positive data from a clinical drug-drug interaction (DDI) study investigating the potential effect of the CYP3A4 enzyme on brilaroxazine in healthy subjects supports no clinically significant interaction when combined with CYP3A4 inhibitors. Reviva believes that a full battery of regulatory compliant toxicology and safety pharmacology studies has been completed for brilaroxazine. Reviva intends to develop brilaroxazine for other neuropsychiatric indications including bipolar disorder, major depressive disorder (MDD) and attention-deficit/hyperactivity disorder (ADHD).
Additionally, brilaroxazine has shown promising nonclinical activity for inflammatory diseases psoriasis, pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) with mitigation of fibrosis and inflammation in translational animal models. Brilaroxazine has already received Orphan Drug Designation by the FDA for the treatment of PAH and IPF conditions. To learn more about the clinical and preclinical data available for brilaroxazine, please visit revivapharma.com/publications.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com
